The UK’s health regulator Medicines and Healthcare Products Regulatory Agency (MHRA) inspected Wockhardt’s L-1 Chikalthana drug manufacturing plant and “there were no critical observations, the company said in a statement on Monday.
Wockhardt shares were trading over 2 per cent up on Tuesday after the company said that UK’s health regulator Medicines and Healthcare Products Regulatory Agency (MHRA) has found “no critical observations” at its L-1 Chikalthana drug manufacturing plant.
The UK’s health regulator Medicines and Healthcare Products Regulatory Agency (MHRA) inspected Wockhardt’s L-1 Chikalthana drug manufacturing plant and “there were no critical observations, the company said in a statement on Monday.
At 11.12 am, Wockhardt shares were yup 2.89 per cent up at Rs 1585.65. Sensex was up 84.43 points at 26,869.98 during the same time.
The MHRA withdrew the Chikalthana plant’s quality certificate two years ago, citing quality control lapses.
Imports from the plant have been banned by the US Food and Drug Administration since November 2013.
With Reuters inputs
| Subscribe To Our Free Newsletter |
